Home/Filings/4/0001415889-25-022386
4//SEC Filing

York Charles N II 4

Accession 0001415889-25-022386

CIK 0001845337other

Filed

Aug 18, 8:00 PM ET

Accepted

Aug 19, 7:40 PM ET

Size

20.4 KB

Accession

0001415889-25-022386

Insider Transaction Report

Form 4
Period: 2025-08-15
Transactions
  • Exercise/Conversion

    Common Stock

    2025-08-15+1,375266,606 total
  • Exercise/Conversion

    Common Stock

    2025-08-15+6,625275,481 total
  • Sale

    Common Stock

    2025-08-18$6.77/sh4,106$27,786278,000 total
  • Exercise/Conversion

    Restricted Stock Unit (RSU)

    2025-08-156,62559,625 total
    Common Stock (6,625 underlying)
  • Exercise/Conversion

    Common Stock

    2025-08-15+6,625282,106 total
  • Exercise/Conversion

    Restricted Stock Unit (RSU)

    2025-08-151,3751,375 total
    Common Stock (1,375 underlying)
  • Exercise/Conversion

    Restricted Stock Unit (RSU)

    2025-08-152,25011,250 total
    Common Stock (2,250 underlying)
  • Exercise/Conversion

    Common Stock

    2025-08-15+2,250268,856 total
  • Exercise/Conversion

    Restricted Stock Unit (RSU)

    2025-08-156,62586,125 total
    Common Stock (6,625 underlying)
Footnotes (5)
  • [F1]Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock upon settlement for no consideration.
  • [F2]The sale of shares is for the sole purpose of covering the Reporting Person's tax liability with respect to the settlement of RSUs.
  • [F3]The price reported in Column 4 is a weighted average price. These shares were sold as part of block trades for multiple security holders of the Issuer at prices ranging from $6.65 to $6.87, inclusive. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein with regard to the block trade.
  • [F4]The RSUs will vest as to 1/16th of the total award in quarterly installments on February 15, May 15, August 15 and November 15, subject to the Reporting Person's provision of service to the Issuer on each vesting date.
  • [F5]RSUs do not expire; they either vest or are canceled prior to the vesting date.

Issuer

Day One Biopharmaceuticals, Inc.

CIK 0001845337

Entity typeother

Related Parties

1
  • filerCIK 0001655962

Filing Metadata

Form type
4
Filed
Aug 18, 8:00 PM ET
Accepted
Aug 19, 7:40 PM ET
Size
20.4 KB